Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Non-cash Items (2021 - 2025)

Historic Non-cash Items for Rani Therapeutics Holdings (RANI) over the last 5 years, with Q3 2025 value amounting to $6.4 million.

  • Rani Therapeutics Holdings' Non-cash Items fell 7065.66% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year decrease of 7065.66%. This contributed to the annual value of $5.2 million for FY2024, which is 9997.2% up from last year.
  • Per Rani Therapeutics Holdings' latest filing, its Non-cash Items stood at $6.4 million for Q3 2025, which was down 7065.66% from $6.5 million recorded in Q2 2025.
  • Rani Therapeutics Holdings' 5-year Non-cash Items high stood at $27.8 million for Q1 2022, and its period low was $57806.0 during Q3 2021.
  • Over the past 5 years, Rani Therapeutics Holdings' median Non-cash Items value was $6.4 million (recorded in 2025), while the average stood at $9.1 million.
  • Per our database at Business Quant, Rani Therapeutics Holdings' Non-cash Items soared by 137373.63% in 2022 and then crashed by 7065.66% in 2025.
  • Quarter analysis of 5 years shows Rani Therapeutics Holdings' Non-cash Items stood at $976000.0 in 2021, then dropped by 12.71% to $851908.0 in 2022, then surged by 1470.24% to $13.4 million in 2023, then tumbled by 61.41% to $5.2 million in 2024, then rose by 23.91% to $6.4 million in 2025.
  • Its Non-cash Items was $6.4 million in Q3 2025, compared to $6.5 million in Q2 2025 and $16.4 million in Q1 2025.